Efgartigimod
Efgartigimod is an FcRn antagonist that lowers circulating IgG, including pathogenic autoantibodies. It is approved in generalized myasthenia gravis and has been evaluated in other IgG-mediated diseases, including thyroid eye disease (the UplighTED program).
Also known as: VYVGART, ARGX-113
Efgartigimod forecasting benchmarks
1 benchmarkMechanism & molecular targets
Indications studied
Developed by
About Efgartigimod
What is Efgartigimod?
Efgartigimod is an FcRn antagonist that lowers circulating IgG, including pathogenic autoantibodies. It is approved in generalized myasthenia gravis and has been evaluated in other IgG-mediated diseases, including thyroid eye disease (the UplighTED program). It is a fcrn antagonist (antibody fragment) developed by argenx.
What does Efgartigimod target?
Efgartigimod acts on Neonatal Fc receptor (FcRn).
How well do AI models predict Efgartigimod trial outcomes?
Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.